RT Journal Article
SR Electronic
T1 Predictive targeting of mitochondrial metabolism in Acute Myeloid Leukemia patients with a lipoic acid analog
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.03.21257935
DO 10.1101/2021.06.03.21257935
A1 Reid, Michael A.
A1 Bose, Shree
A1 Pladna, Kristin M
A1 Anderson, Rebecca
A1 Mikhael, Peter G.
A1 Xiao, Zhengtao
A1 Dai, Ziwei
A1 Liu, Shiyu
A1 Liu, Juan
A1 Pardee, Timothy S.
A1 Locasale, Jason W.
YR 2021
UL http://medrxiv.org/content/early/2021/06/04/2021.06.03.21257935.abstract
AB Targeting metabolism has long been a theory for cancer therapy, but clinical development has been limited by toxicities, compound availability, overall efficacy, and patient specificity1. CPI-613, a lipoic acid analogue that interferes with enzymes involved in mitochondrial metabolism, has demonstrated clinical activity in lethal malignancies including relapsed or therapy refractory Acute Myeloid Leukemias (AMLs)2,3 and Phase III trials are ongoing1. Using metabolomics, we investigated blood and bone marrow samples from a cohort of 29 relapsed or refractory AML patients involved in Phase I and II studies undergoing CPI-613 treatment (NCT01768897, NCT02484391) including 13 that achieved a complete response. We show that CPI-613 treatment in patients induced defined alterations related to the tricarboxylic acid (TCA) cycle and associated redox, anabolic and catabolic metabolism. These findings are consistent with targeting of several ketoacid dehydrogenase (KADH) enzymes that use lipoic acid as a cofactor and are related to mitochondrial metabolism. The alterations were observed systemically but were more pronounced within the leukemic bone marrow microenvironment consistent with its mechanistic target. Machine learning revealed that metabolic status and changes associated with mitochondrial metabolism were predictive of treatment response, indicating that mechanism-based metabolite biomarkers to a targeted metabolic cancer therapy may be feasible. Finally, we confirm using isotope tracing and flux analysis that these effects are due to disruptions to substrate utilization into the mitochondria. Our findings provide evidence that a tolerated, anti-cancer therapeutic can act by targeting mitochondrial metabolism in humans.Competing Interest StatementT.S.P. consults for and is the Co-Chief Medical Officer of Rafael Pharmaceuticals. J.W.L advises Nanocare Technologies, Restoration Foodworks and Raphael Pharmaceuticals. J.W.L received no funding and no payment from Raphael Pharmaceuticals for this study. All other authors declare no competing interests.Clinical TrialNCT01768897, NCT02484391Funding StatementR01CA193256 to J.W.L., R01CA197991-05 to TSP) and the American Cancer Society (129832-RSG-16-214-01-TBE to J.W.L. and 131615-PF-17-210-01-TBE to M.A.R.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were obtained following signed informed consent and all protocols were approved by the Wake Forest Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll source code generated for data analysis and metabolomics data sets are available at https://github.com/LocasaleLab/Locasale-lab-2020-lipoic-acid-analog-study. https://github.com/LocasaleLab/Locasale-lab-2020-lipoic-acid-analog-study